• Home
• About
• Login
• Register
• Search
• Current
• Archives
• Announcements
• Books For Review
• Manuscript Submission
• Editorial Review Board
• Permissions and Licensing
• Advertising Information
• Library Referral Form
• Reprints
• Register
• Subscription Information
• Call for Papers - Legal and Regulatory aspects of Opioids
• Privacy
• Special Issue on Buprenophine
• User License Agreement
• BUPE2021
• Webinars

Home > Archives > Vol 17, No 7 (2021)

Table of Contents

Editorial

Alan Cowan: Buprenorphine from the bench to the bedside—Personal notes Saadet Inan, MD, PhD, Michael Guarnieri, PhD, MPH

PDF 5-7

From the publisher Richard A. DeVito, Jr.

PDF 8

Buprenorphine: Not a silver bullet, and still controversial Sudheer Potru, DO, FASAM, Michael Sprintz, DO, DFASAM, Antje M. Barreveld, MD, Lynn Kohan, MD

PDF 9-10

Buprenorphine not a silver bullet but an opioid of choice for chronic pain Mellar P. Davis, MD, FCCP, FAAHPM, Jeffrey Fudin, PharmD, FACCP, FASHP, FFSMB

PDF 11-14

Articles

Buprenorphine blood concentrations: A biomarker for analgesia Michael Guarnieri, PhD, MPH

PDF 15-20

Emerging pharmacologic mechanisms of buprenorphine to explain experience of analgesia versus adverse effects Jeffrey Bettinger, PharmD, Himayapsill Batista Quevedo, PharmD, Jacqueline Cleary, PharmD, BCACP

PDF 21-31

Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy Aamer Attaar, PharmD, BCPS, Molly Curran, PharmD, BCPS, BCCCP, Lyndsi Meyenburg, PharmD, BCPS, Richard Bottner, DHA, PA-C, Clarissa Johnston, MD, Kirsten Roberts Mason, PharmD, BCPS

PDF 33-41

A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain Michael D. Komrowski, MS, Nitin K. Sekhri, MD

PDF 43-50

Dispensing of medications used in MAT for Medicare Part D beneficiaries: Impact of 2016 CARA Chris Gillette, PhD, Catherine Shull, PA-C, MPAS, Sarah J. Garvick, MS, MPAS, PA-C, Lindsey Mitchell, MSM, MMS, PA-C, Julienne Kirk, PharmD

PDF 51-57

Interest in long-acting injectable buprenorphine among syringe services program participants Hannah Epstein, BS, Andres Perez-Correa, MD, Jason Beltre, BS, Christine Fitzsimmons, ASN, Pia Marcus, BA, Franklin Ramirez, BA, L. Synn Stern, RN, MPH, Brianna L. Norton, DO, MPH, Aaron D. Fox, MD, MS, Andrea Jakubowski, MD, MS

PDF 59-67

Buprenorphine not detected on urine drug screening in supervised treatment Nazila Jamshidi, MBBS, FRACP, FAChAM, BPharm (hons), PhD, Akshay Athavale, MBBS, FRACP, BPharm (hons), MMed, Bridin Murnion, MBChB, FRACP, FFPMANZCA, FAChAM

PDF 69-76

Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access Elizabeth Kolb, MS, Mark Rueth, PharmD

PDF 77-86

Geographic analysis of military health system (MHS) buprenorphine prescribers and patients Fuad Issa, MD, FAPA, Christine Nguyen, MHA, PMP, Orolo Davies Abili, PharmD, Ruth F. Quah, MPH, Michael I. Engler, MPH, Jennifer G. Greenberg, MPH, MAJ Raquel Giunta, PharmD, BCPS, CAPT Paul A. Gobourne, MSN, BC-FNP, Amy J. Osik, MS, CDR John A. Hodgson MD, Christopher Spevak, MD, MPH, JD

PDF 87-100

The divided dose approach to perioperative buprenorphine management in patients with opioid use disorder Amanda L. Engle, PharmD, Amanda R.M. Winans, PharmD, Linda Demma, MD, PhD, Jacqueline Cleary, PharmD

PDF 101-107

Atypical opioids and their effect on respiratory drive Lynn Webster, MD, Richard L. Rauck, MD

PDF 109-118

Review Articles

Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment Abhishek Ghosh, MD, DM, Chandrima Naskar, MD, Fazl-e Roub, MD, DM, Debasish Basu, MD, DNB, MAMS

PDF 119-131

Adverse effects of regulation on buprenorphine prescribing and its impact on the treatment of opioid use disorder Daniel M. Strickland, MD, FACOG, John Sorboro, MD, DABPN, FASAM

PDF 133-139

A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine–naloxone tablets Tamoud Modak, MD, DM, Siddharth Sarkar, MD, MRCPsych, Yatan Pal Singh Balhara, MD

PDF 141-152

Case Studies

Facilitating discontinuation of intravenous opioids by concurrent use of sublingual buprenorphine with rapid microdosing induction: A pain management case study Arjun Tara, DO, Gregory Acampora, MD, Jingping Wang, MD, PhD, Karina De Sousa, BS, Yi Zhang, MD, PhD

PDF 153-158

Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach René C. Vytialingam, MBBS, FRACGP, FAChAM, Stephan A. Schug, MD, FANZCA, FFPMANZCA, EDPM, Richard O’Regan, MBBS, FAChAM

PDF 159-166

Clinical Report

Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: “A case series” Gurpreet Singh, MBBS, Jaya Sri Konakanchi, MBBS, Brandon Betsch, Aastha Thapa, Roopa Sethi, MD

PDF 167-170

Perioperative outcomes for patients on chronic buprenorphine undergoing spine surgery: A case series Ashley L. Sharp, MD, Stephanie Gilbert, MD, Danielle N. Perez, MD, Kerstin Kolodzie, MD, PhD, MAS, Matthias Behrends, MD

PDF 171-177

A case report of satisfactory post-left knee replacement pain control after switching from oxycodone to buprenorphine Shuo Qiu, MD, Sachinder Vasudeva, MD

PDF 179-182

Full Issue

Buprenorphine: Clinical and Public Policy Implications

PDF 1-182